Any time a biopharma company is developing a new therapeutic area, it’s very important to think ahead—well before launch—about breaking down any potential access barriers.
Companies should think about making sure that they can generate evidence to get the approval and recommendations that they’re aiming for, getting payors ready to cover the product, and ensuring that the product is accessible to patients at the appropriate time in the patient journey.
Those areas are at the heart of attorney Richard Hughes’s work.
Richard helps biopharma clients shape the market in advance of launch. In this video, he breaks down some upcoming opportunities and challenges for the biopharma industry and the public health fields.